This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1539 entries already.
Forbion has led a $75 million investment in Altesa BioSciences, positioning the biotech to run a phase IIb trial in chronic obstructive pulmonary disease (COPD) patients in the second quarter.
California-based Unnatural Products, Inc. (UNP) has signed a research collaboration and licensing agreement with Basel-based multinational pharmaceutical company Novartis to develop macrocyclic peptide therapeutics for an undisclosed cardiovascular program.
The French biopharmaceutical company, PLL Therapeutics, announced positive results from a phase I/II clinical trial for its investigational therapy PLL001 to treat amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease that causes degeneration of motor neurons and loss of muscle control.
Axol Bioscience has acquired Newcells Biotech’s ophthalmology business to expand its portfolio of drug discovery and safety testing models.
Setback for Boehringer Ingelheim: the company has halted development of its inhaled gene therapy BI 3720931 for cystic fibrosis after a phase 1/2 trial failed to deliver efficacy data supporting further progress. While the safety profile met expectations, the programme has now been shelved.
Years of uncertainty surrounding the numerous pending lawsuits against Bayer’s Monsanto unit could now be brought to an end through a costly but capped court settlement. Under the proposed agreement, Bayer would pay up to roughly 7 billion US dollars over around 20 years to resolve claims for damages.
The share price of London-based Compass Pathways soared over 30% on Tuesday after the company reported that its synthetic psilocybin formulation COMP360 had met the primary endpoint in the second of two pivotal phase III trials in treatment-resistant depression (TRD), confirming consistent results across 839 patients and clearing the path toward what would be the first regulatory filing of a classic psychedelic for a psychiatric indication.
Swedish startup CubaseBio has raised €5.9 million in blended financing to advance its next-generation 3D spatial transcriptomic technology. Of that total, €3.9 million comes from private capital. Voima Ventures and Nordic Science Investments led the private financing. Illumina Ventures, Almi Invest, Life Science Invest and several genomics-focused private investors also participated.
Newron Pharmaceuticals has secured up to €38mn to advance Phase III trials of evenamide, a drug that, if successful, could represent one of the first circuit-modulating therapies in schizophrenia.
The European Innovation Council (EIC) has funded the collaborative GLIOBREAK project, bringing together Swedish biotech Beactica Therapeutics and the Belgian KU Leuven Institute for Single-Cell Omics (LISCO) to advance Beactica’s small-molecule candidate, BEA-17, as a precision immunotherapy for glioblastoma, the most common and aggressive form of brain cancer, which currently has limited treatment options.